Literature DB >> 2990330

In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.

H M Wexler, B Harris, W T Carter, S M Finegold.   

Abstract

An ampicillin-sulbactam combination was compared with ampicillin alone, chloramphenicol, clindamycin, and metronidazole against 272 strains of anaerobic bacteria. Chloramphenicol and ampicillin-sulbactam were the most effective, inhibiting 98 to 99% of strains tested at breakpoint (16 micrograms/ml). The combination of sulbactam and ampicillin was much more effective than ampicillin alone against Bacteroides fragilis strains but did not differ substantially from ampicillin alone against Fusobacterium spp., gram-positive rods, and gram-positive cocci.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990330      PMCID: PMC180171          DOI: 10.1128/AAC.27.5.876

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Identification and antimicrobial susceptibility of 250 Bacteriodes fragilis subspecies tested by broth microdilution methods.

Authors:  R N Jones; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

2.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.

Authors:  M A Crosby; D W Gump
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

4.  Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

5.  The effect of inhibitors of beta-lactamases on beta-lactamase extracts and on intact cells.

Authors:  J T Li; F Moosdeen; J D Williams
Journal:  J Antimicrob Chemother       Date:  1982-04       Impact factor: 5.790

6.  Treatment of infections caused by ampicillin-resistant pathogens with a combination of ampicillin and CP-45,899.

Authors:  J F Plouffe
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

7.  In-vitro evaluation of sulbactam, a penicillanic acid sulphone with beta-lactamase inhibitory properties.

Authors:  D Greenwood; A Eley
Journal:  J Antimicrob Chemother       Date:  1982-08       Impact factor: 5.790

8.  Antibiotic susceptibility of the subspecies of Bacteroides fragilis.

Authors:  D J Blazevic
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

9.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

10.  CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.

Authors:  J A Retsema; A R English; A E Girard
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

View more
  17 in total

1.  Spiral gradient endpoint method compared to standard agar dilution for susceptibility testing of anaerobic gram-negative bacilli.

Authors:  G B Hill
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

2.  In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.

Authors:  H M Wexler; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

3.  Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid.

Authors:  P C Fuchs; A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

4.  Ampicillin plus sulbactam in vitro activity against anaerobes.

Authors:  F Heilmann; W Heizmann; H Werner
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 5.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

6.  Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

7.  Sulbactam/ampicillin versus cefotaxime as initial therapy in serious soft tissue, joint and bone infections.

Authors:  L Löffler; A Bauernfeind; W Keyl
Journal:  Drugs       Date:  1988       Impact factor: 9.546

8.  Effect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 9.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

10.  Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections.

Authors:  A P Walker; R L Nichols; R F Wilson; B A Bivens; D D Trunkey; C E Edmiston; J W Smith; R E Condon
Journal:  Ann Surg       Date:  1993-02       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.